deltatrials
Recruiting PHASE1 INTERVENTIONAL 3-arm NCT03370406

Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC

Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Calcipotriene in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities

Sponsor: Melissa Pugliano-Mauro

Conditions Carcinoma, Squamous Cell
Interventions 5-fluorouracil Calcipotriene
Updated 18 times since 2017 Last updated: Jun 10, 2025 Started: Aug 3, 2018 Primary completion: Sep 30, 2026 Completion: Oct 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03370406, this PHASE1 trial focuses on Carcinoma, Squamous Cell and remains actively recruiting participants. Sponsored by Melissa Pugliano-Mauro, it has been updated 18 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Jan 2019 · 4 months · monthly snapshot~Jan 2019 – ~Oct 2019 · 9 months · monthly snapshot~Oct 2019 – ~Feb 2020 · 4 months · monthly snapshot~Feb 2020 – ~Nov 2020 · 9 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Nov 2022 · 13 months · monthly snapshot~Nov 2022 – ~Aug 2023 · 9 months · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jul 2025 · 8 months · monthly snapshot~Jul 2025 – present · 12 months · monthly snapshot

Change History

18 versions recorded

  1. Jul 2025 — Present [monthly]

    Recruiting PHASE1

  2. Nov 2024 — Jul 2025 [monthly]

    Recruiting PHASE1

  3. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  5. Dec 2023 — Jul 2024 [monthly]

    Recruiting PHASE1

▶ Show 13 earlier versions

  1. Oct 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  2. Aug 2023 — Oct 2023 [monthly]

    Recruiting PHASE1

  3. Nov 2022 — Aug 2023 [monthly]

    Recruiting PHASE1

  4. Oct 2021 — Nov 2022 [monthly]

    Recruiting PHASE1

  5. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  6. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  7. Feb 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  8. Oct 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

  9. Jan 2019 — Oct 2019 [monthly]

    Recruiting PHASE1

  10. Sep 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  11. Aug 2018 — Sep 2018 [monthly]

    Not Yet Recruiting PHASE1

  12. Jun 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE1

  13. Dec 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Melissa Pugliano-Mauro
  • National Cancer Institute (NCI)
Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations